Project Grant R01HL181504
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $863,551 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to improve external validity of the RECHARGE trial through a partially randomized patient preference framework. The RECHARGE program comprises two integrated multicenter randomized trials—RECHARGE:WOMEN and RECHARGE:MINORITIES—that compare percutaneous coronary intervention (PCI) versus coronary artery...
- The National Heart, Lung, and Blood Institute awarded Emory University $204,803 on March 7, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate an electrocardiogram-based deep learning model that predicts coronary artery calcium and adverse cardiovascular outcomes in South Asian populations. The project addresses the underestimation of atherosclerotic cardiovascular disease risk in South Asians through an artificial intelligence approach applied to...
- The National Heart Lung and Blood Institute awarded the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $852,991 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a longitudinal study of coronary inflammation detection using computed tomography. The recipient will measure epicardial fat density and peri-coronary fat attenuation in 17,138 non-contrast cardiac CT scans drawn from the Multi-Ethnic Study of Atherosclerosis...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $802,973 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop rapid point-of-care molecular imaging of immune activation in acute coronary syndrome and acute myocarditis using targeted microbubble contrast agents. The project applies myocardial contrast echocardiography with phosphatidylserine-incorporating lipid microbubbles (MB-PS) to detect inflammatory activation from...
- The National Heart Lung and Blood Institute awarded Case Western Reserve University $1,573,126 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an artificial intelligence-based decision-support tool that identifies patients at risk of myocardial ischemia using low-cost or no-cost screening data. The tool will analyze CT calcium scores, electrocardiogram data, and clinical risk factors to serve as a gatekeeper strategy for determining which patients...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $174,621 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance imaging (CMR) techniques for monitoring congenital heart disease using ultra-low field (ULF) MRI systems. The recipient will adapt CMR to an inexpensive, unshielded, open-geometry ULF MRI system and apply machine learning techniques to mitigate hardware limitations and...
- The National Heart, Lung, and Blood Institute awarded Emory University $788,336 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 10, 2026, to develop and validate a radiomic-based integrated cancer treatment benefit and cardiovascular outcome risk scale (RICTOR SCALE). The project runs through May 31, 2030, with place of performance in Atlanta, Georgia. The RICTOR SCALE combines machine-learning analysis with clinical data to concurrently characterize immunotherapy...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $133,221 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate precision electrophysiology imaging techniques for localizing cardiac arrhythmias. The recipient will use computed tomography and echocardiography imaging combined with electroanatomical mapping data to create three-dimensional visualization of arrhythmia...
- The National Heart, Lung, and Blood Institute awarded Case Western Reserve University $109,076 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop improved cardiovascular risk prediction models using advanced computational methods applied to cardiac CT imaging. The research applies deep learning to detect small, low-density calcifications on coronary artery calcium score exams that are predictive of early-stage atherosclerosis and near-term...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $186,840 under CFDA 93.837 Cardiovascular Diseases Research on July 3, 2026, for advanced analysis of high-resolution cardiac diffusion tensor imaging (DTI). The funded work develops and applies DTI phenomapping, a voxel-level quantitative analysis approach for cardiac magnetic resonance imaging that resolves distinct microstructural patterns in...
The National Heart, Lung, and Blood Institute awarded Emory University $651,762 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct the RECHARGE: Imaging Ancillary Study, a noninvasive coronary imaging investigation nested within two ongoing PCORI-funded randomized controlled trials (RECHARGE:WOMEN and RECHARGE:MINORITIES). The study will leverage 600 women and 600 Black or Hispanic patients enrolled across 100 sites in the United States and Canada in the parent RECHARGE trials, which randomize patients with left main or multivessel coronary artery disease requiring revascularization to percutaneous coronary intervention or coronary artery bypass grafting. The ancillary study will perform baseline coronary CT angiography (CCTA) on 300 women and 300 Black or Hispanic patients before revascularization to characterize coronary plaque morphology, composition, and peri-coronary inflammation using artificial intelligence-enabled radiographic analysis. These AI-derived biomarkers will correlate plaque features with major adverse cardiovascular events (death, spontaneous myocardial infarction, repeat revascularization) tracked over approximately 5 years in the parent trials, with 10-year follow-up anticipated. The work addresses a knowledge gap regarding coronary plaque and inflammatory characteristics in underrepresented populations referred for revascularization. Industry has committed more than $1.6 million in support-in-kind. Performance occurs in Atlanta, Georgia, with a period of performance through June 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 8/28/26 | ||
| Not listed | $651.8k | 8/27/26 |